Clinical Trials in Florida

Showing 7401-7420 of 12,796 trials

Adaptive-design Dose Finding Study to Assess the Antiviral Efficacy and Safety of NIM811 Administered in Combination With Standard of Care (SOC) in Relapsed Hepatitis C Virus 1 (HCV-1) Infected Patients

NCT00983060

This is a study designed to identify a dose of NIM811 that has a good safety profile, is well tolerated when co-administered with SOC, and provides a clinically meaningful effect in viral load reduction compared to SOC alone. This information will be used to support doses selected for future studies.

Chronic Hepatitis C Genotype-1 Relapse

Novartis Pharmaceuticals59 participantsStarted Sep 2009

San Diego, California, United States • Orlando, Florida, United States • Sarasota, Florida, United States +13 more locations

COMPLETEDPhase 249 miles

Efficacy and Safety of Patupilone in Men (≥18 Years) With Metastatic Hormone Refractory Prostate Cancer

NCT00411528

The objective of this study is to assess the response of patupilone plus prednisone compared to docetaxel plus prednisone on prostate specific antigen (PSA) in patients with metastatic hormone refractory prostate cancer. Additionally, this study will assess the response on measureable disease and the effects on patient-reported outcomes.

Metastatic Hormone Refractory Prostate Cancer

Novartis Pharmaceuticals185 participantsStarted Sep 2006

La Jolla, California, United States • Aurora, Colorado, United States • Norwalk, Connecticut, United States +29 more locations

Adaptive-design Dose Finding Study to Assess the Antiviral Efficacy and Safety of NIM811 Administered in Combination With Standard of Care (SOC) in Relapsed Hepatitis C Virus 1 (HCV-1) Infected Patients

Efficacy and Safety of Patupilone in Men (≥18 Years) With Metastatic Hormone Refractory Prostate Cancer

Find Trials by Condition in Florida

Pharmacokinetics of LCQ908 in Patients With Hepatic Impairment

Clinical Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEZ763

Study to Evaluate the Pharmacokinetics of Firsocostat or Fenofibrate in Adults With Normal and Impaired Hepatic Function

Dose Finding Study for QAW039 in Asthma

Tifacogin for the Treatment of Patients With Severe Community-Acquired Pneumonia

Safety and Efficacy of Multiple Daily Dosing of Oral LFF571 in Patients With Moderate Clostridium Difficile Infections

Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors

Efficacy of QAX576 in Asthma

A Trial l of Panobinostat Given in Combination With Trastuzumab and Paclitaxel in Adult Female Patients With HER2 Positive Metastatic Breast Cancer

Helicobacter Pylori Genome Project (HpGP)

Long-Term Safety and Efficacy of rFIXFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia B

Safety Study of LBH589 When Given in Combination With Lenalidomide and Dexamethasone in Adult Patients With Multiple Myeloma.

Efficacy of SBR759 in Lowering Serum Phosphate Levels in Chronic Kidney Disease Patients on Hemodialysis

Study of INC280 in Patients With c-MET Dependent Advanced Solid Tumors

Pharmacokinetics and Safety of rFVIIIFc Manufactured at 15,000 L (15K) Scale

PCA062 in pCAD-positive Tumors.

A Phase I-Ib/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bortezomib, With or Without Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma.

Pharmacokinetics of rFVIIIFc at Two Vial Strengths